- Home
- BB vs IDYA Comparison
BB vs IDYA Comparison
Compare BB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- IDYA
- Stock Information
- Founded
- BB 1984
- IDYA 2015
- Country
- BB Canada
- IDYA United States
- Employees
- BB N/A
- IDYA N/A
- Industry
- BB
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- BB
- IDYA Health Care
- Exchange
- BB Nasdaq
- IDYA Nasdaq
- Market Cap
- BB 1.8B
- IDYA 1.5B
- IPO Year
- BB 1997
- IDYA 2019
- Fundamental
- Price
- BB $3.81
- IDYA $17.42
- Analyst Decision
- BB Buy
- IDYA Strong Buy
- Analyst Count
- BB 7
- IDYA 13
- Target Price
- BB $4.43
- IDYA $53.58
- AVG Volume (30 Days)
- BB 12.1M
- IDYA 1.4M
- Earning Date
- BB 06-25-2025
- IDYA 05-06-2025
- Dividend Yield
- BB N/A
- IDYA N/A
- EPS Growth
- BB N/A
- IDYA N/A
- EPS
- BB N/A
- IDYA N/A
- Revenue
- BB $534,900,000.00
- IDYA $7,000,000.00
- Revenue This Year
- BB N/A
- IDYA $121.20
- Revenue Next Year
- BB $9.15
- IDYA $302.20
- P/E Ratio
- BB N/A
- IDYA N/A
- Revenue Growth
- BB N/A
- IDYA N/A
- 52 Week Low
- BB $2.01
- IDYA $13.45
- 52 Week High
- BB $6.24
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- BB 62.07
- IDYA 43.87
- Support Level
- BB $3.27
- IDYA $16.82
- Resistance Level
- BB $3.95
- IDYA $21.43
- Average True Range (ATR)
- BB 0.14
- IDYA 1.16
- MACD
- BB 0.10
- IDYA -0.16
- Stochastic Oscillator
- BB 81.88
- IDYA 13.02
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.